The ability of VJ to overcome AKT/Notch1 overexpression and to serve as a potential inhibitor of cancer progression was evident in vivo results, wherein cell proliferation and tumor burden were significantly reduced in the AKT/HCT 116 xenografts. The gene discussed is AKT1; the disease is cancer.